Shurrab M, Danon A, Alnasser S, et al. - By analyzing data from relevant randomized controlled trials identified through systematic explorations of various major databases from their inception through September 2019, researchers evaluated results between dual-antithrombotic therapy with the use of direct-acting oral anticoagulants (DOACs) plus an antiplatelet agent (dual therapy) vs warfarin plus 2 antiplatelet agents (triple therapy) for atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) or with acute coronary syndrome (ACS). The analysis included 4 randomized controlled trials, involving 7,168 patients. Findings revealed less major bleeding and less major bleeding or clinically relevant nonmajor bleeding reported in relation to the use of dual-antithrombotic therapy with DOACs vs triple therapy in patients with AF and recent ACS or PCI. Nonsignificantly higher composite of mortality and ischemic events was revealed in relation to the use of dual therapy, without a difference in mortality.